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Death-Associated Protein Kinase 1 (DAPK1) belongs to a family of five serine/threonine
(Ser/Thr) kinases that possess tumor suppressive function and also mediate a wide
range of cellular processes, including apoptosis and autophagy. The loss and gain-
of–function of DAPK1 is associated with various cancer and neurodegenerative diseases
respectively. In recent years, mechanistic studies have broadened our knowledge
of the molecular mechanisms involved in DAPK1-mediated autophagy/apoptosis. In
the present review, we have discussed the structural information and various cellular
functions of DAPK1 in a comprehensive manner.
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INTRODUCING DAPK1
Death-associated protein kinase 1 (DAPK1), a part of a family of Ser/Thr kinase, was originally
isolated in an unbiased antisense based genetic screen for genes whose protein products were
imperative for interferon Gamma (IFN-γ) induced death in HeLa cells (Deiss et al., 1995), and
identified by a functional cloning based on its involvement in interferon-γ-induced apoptosis
(Bialik and Kimchi, 2006).
DAPK1 is an important regulator of cell death and autophagy which act as a critical
component in the ER stress-induced cell death pathway (Gade et al., 2014). It is a stress-responsive
serine/threonine (Ser/Thr) kinase (Hainsworth et al., 2010), which constitutes a critical
integration point in ER stress signaling, transmitting these signals into two distinct directions,
Abbreviations: DAPK1, Death-Associated Protein kinase 1; Ser/Thr, serine/threonine; IFN, interferon; Ca2+/CaM,
Ca2+/calmodulin; ROC, Ras of complex proteins; COR, C-terminal of ROC; PDB, Protein Data Bank; HRD, His-Arg-
Asp; Hsp90, heat shock protein 90; MIB-1, mindbomb E3 ubiquitin ligase 1; DIP-1, DAPK1 interacting protein-1;
CHIP, carboxyl terminus of HSC70-interacting protein; GTP, guanosine triphosphate; GDP, guanosine diphosphate;
Pin1, peptidyl prolyl isomerase 1; TNF, tumor necrosis factor; TRADD, TNF receptor type 1-associated death domain
protein; FADD, Fas-associated protein with death domain; ERK, extracellular signal regulated; BTB, beta–turn-
beta; KLHL20, kelch-like protein20; MARK, MT affinity regulating kinase; PKM2, pyruvate kinase isoform M2;
UNC5H2, Unc-5 homolog 2; TSC2, tuberous sclerosis 2; Rheb, Ras homolog enriched in brain; mTOR, mechanistic
target of rapamycin; TGF, transforming growth factor; Apaf1, Apoptotic protease activating factor 1; Mdm 2,
mouse double minute 2 homolog; MEFs, mouse embryonic fibroblasts; ARF, alternate reading frame; REFs, rat
embryonic fibroblasts; Bcl-2, B-cell lymphoma 2; BH3, Bcl-2 homology domain 3; ROCK1, rho-associated, coiled-
coil-containing protein kinase 1; PKD, protein kinase D; PI3P, phosphatidyl inositol-3 phosphate; DFCP1, Double
FYVE-domain containing protein 1; HMGB1, high mobility group box 1; TRAF6, TNF receptor-associated factor 6;
JNK, c-Jun N-terminal kinase; MAPK3K, mitogen-activated protein kinase 3K; ASK1, Apoptosis signal-regulating
kinase 1; MARKs, microtubule affinity regulating kinases; MAPs, microtubule associated proteins; NDC, neuronal
death signaling complex; NMDA, N-methyl-D-aspartate; AD, Alzheimer’s disease; LOAD, late-onset Alzheimer’s
disease; MT, microtubule; KD, kinase domain; R1D, repeat binding domain 1; ANP, Phosphoaminophosphonic Acid-
Adenylate Ester.
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caspase activation and autophagy, leading to cell death (Gozuacik
et al., 2008). DAPK1 is a mediator of pro-apoptotic pathway,
involved in multiple cell death processes induced by various
internal and external apoptotic stimulants (Celik et al., 2015).
This pro-apoptotic Ser/Thr kinase regulates both type I
apoptotic (caspase-dependent) and type II autophagic (caspase-
independent) cell death signal (Shohat et al., 2001). On the
other hand, DAPK1 is a tumor suppressor gene, known to
suppress tumor growth and metastasis by promoting autophagy
and apoptosis (Bialik and Kimchi, 2006).
It has been hypothesized that DAPK1 play a role in perinatal
brain injury via the observation of highly expressed DAPK1
mRNA level in the developing brain (Nair et al., 2013). In a recent
study, DAPK1 is identified as a new component of the neuronal
death signaling complex (NDC; Lai et al., 2011), which act as a
signaling amplifier of N-methyl-D-aspartate (NMDA) receptors
at extrasynaptic sites for mediating brain damage in stroke
(Tu et al., 2010). Cerebral ischemia recruits DAPK1 into the
NMDA receptor complex through its direct binding to the amino
acid residues 1292–1304 of the N-methyl D-aspartate receptor
subtype 2B (NR2B) carboxyl terminus (NR2B-CT1292–1304). This
direct DAPK1-NR2B interaction thereby potentiating NR2BR
activity via triggering the DAPK1-mediated phosphorylation of
NR2B subunit at Ser-1303 (Lai et al., 2011) inducing injurious
Ca2+ influx through NMDA receptor channels, results in
an irreversible neuronal death. Here DAPK1 seems to be a
promising target for drug development, especially with the
aim of preventing the neuronal apoptosis after stroke as it
has a central role in neuronal cell death (Bialik and Kimchi,
2004) and represents a relatively unique enzyme in the protein
kinase superfamily whose biological functions are related to both
signal-mediated apoptosis and autophagy (Stevens and Hupp,
2008).
The DAPK1 gene is quite conserved in evolution from
various invertebrates, such as C. elegans (Tong et al., 2009),
to chordates and mammals, maps to mouse chromosome
13 and human chromosome 9 and transcribed into a single
mRNA of 6.3 kb encoded for a structurally unique 160-kD
Ca2+/calmodulin (CaM)-dependent serine-threonine kinase
(Deiss et al., 1995; Nair et al., 2013). DAPK1 is the largest
one in the DAPK protein family, consisting of 1430 amino
acids (Refseq: accession NM_004938.2), contains Ca2+/CaM
autoregulatory domain, 10 ankyrin repeats, 2 putative P-loop
consensus sites, Ras of complex proteins, C-terminal of ROC
(ROC-COR) domains, which overlap with a cytoskeletal-binding
region, a death domain and a serine-rich C-terminal tail
(Shiloh et al., 2014); whose phosphorylation activity is known
to be responsible for certain forms of apoptotic cell death
(Deiss et al., 1995; Cohen et al., 1997, 1999; Kissil et al.,
1997).
DAPK1 STRUCTURE AND FUNCTION
Drug design is mainly being actively carried out within the DAPK
family on the basis of active conformational structure of the
DAPK1 (Tereshko et al., 2001; Velentza et al., 2001, 2002, 2003;
Bialik and Kimchi, 2004; Yamakawa et al., 2004; McNamara
et al., 2009; Okamoto et al., 2009, 2010). More than 50 crystal
structures of DAPK1, reported in the Protein Data Bank (PDB),
are crystallized with their respective inhibitors with a resolution
higher than 2.5 Angstroms.
The DAPK1 crystal structure, which can be used as the
starting point for designing of bioavailable protein kinase
inhibitor, is an excellent example of a small-molecule fragment
bound to the kinase domain allowing in vivo and in vitro target
validation studies to be performed. However, although initial
target validation evidence supports DAPK1 as a drug discovery
target for neurological disorders, no clinically promising small-
molecule DAPK1 inhibitors have yet been discovered. Therefore,
the attractive treatment option for perinatal brain injury
is the development of a domain specific small molecule
inhibitors for DAPK1 with reduced adverse effects, can easily
be administered and screened for specificity and capacity of
binding with a target. It is important to gain insight into to
understand how the DAPK1, a multi-domain protein operates
in a cellular context, and how its dysfunction leads to disease
(Nair et al., 2013). For this purpose, the structural studies
have been performed describing the precise spatial arrangement
of DAPK1 domains and their known or proposed functions
(Figure 1).
The Catalytic Domain: Structure and
Regulation
The most thoroughly characterized catalytic domain structure
of DAPK1 (PDB ID: 1IG1) was determined at 1.5 Å resolution
and has provided structural hints as to DAPK1’s mechanism of
activation, interactions with substrates, and potential inhibitor
design (Tereshko et al., 2001; Bialik and Kimchi, 2004; Figure 2).
According to this structure, DAPK1 exhibits the canonical kinase
fold, consisting of a small β-stranded N-terminal domain, and
a larger helix-rich C-terminal domain, connected by a hinge
region. The DAPK1 contains catalytic domain at its N-terminus
composed of the typical 11 subunits. In addition, in many of the
available PDB structures, the catalytic domain was crystallized
as homodimer and this interesting dimerization profile was
confirmed by non-covalent nano-electrospray ionization mass
spectrometry (Zimmermann et al., 2010). Another outstanding
feature of DAPK1 structure is positioned on the upper lobe of
the catalytic domain, which is a highly ordered short segment
of mostly positively charged residues, termed as ‘‘basic loop’’
(residues 45–56; Tereshko et al., 2001). These 12 amino acids are
a conserved feature of the DAPK family members thus referred
to as ‘‘the fingerprint’’ of the family (Inbal et al., 2000). Of note,
the basic residues mutation in the loop did not affect the Km
of a peptide substrate (Velentza et al., 2001), indicates indirect
involvement in substrate binding rather may be involved in other
functions. However, this loop was shown to mediate not only
DAPK1 homodimerization as well as homooligomerization via
their shared basic loop motif, but also facilitate physical and
functional interactions. Here the crystal structure of catalytic
domain shows that the kinase is constitutively in the ‘‘closed’’,
active conformation so this feature states that there is no
evidence that DAPK1 require phosphorylation of an activation
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FIGURE 1 | Schematic depiction of multi-domain organization of death associated protein kinase 1 (DAPK1) protein with amino acid numbering
(http://www.uniprot.org/uniprot/P53355), showing different types of interacting proteins/molecules of the various DAPK1 domains and their known
or proposed functions. (Blue colored text indicates an interaction that regulate DAPK1, pink colored text indicates an effector of DAPK1).
loop, a mechanism common to many other kinases (Nolen
et al., 2004). In fact, no activating phosphorylation events
on the catalytic domain of DAPK1 have been reported so
far.
Interestingly, DAPK1 lack His-Arg-Asp (HRD) motif that
require activation loop phosphorylation, common to other
kinases in which the conserved arginine in this motif creates a salt
bridge with the phosphorylated residue in the activation loop. In
DAPK1, a change at residue 138 where the arginine is replaced
by a conserved phenylalanine, substitutes phosphorylation
dependent active-site interactions with a local hydrophobic
core that maintains an active kinase conformation. According
to active site analysis of the X-ray crystallographic structure
of human DAPK1 complex with respective inhibitor (PDB
ID: 1IG1) using Chimera 1.11 version, the active sites of
DAPK1 accommodates certain highly conserved amino acid
residues such as Gln23, Phe24, Lys42, Glu94, Val96, Glu100,
Glu146 and Asp161; involved in H-bond interaction with their
respective ligands and hydrophobic interactions includes Leu19,
Val27, Ile77, Met146 and Ile160. Here, the hydrogen bond
interactions with Val96 and Glu94 are especially important
since they reside in a hydrophobic enclosure. There are some
additional hydrophobic interactions with Ile77 and Leu93.
The amino terminal lobe of the kinase domain contains
an interaction surface for the chaperon heat shock protein
90 (HSP90), which recognizes specific neutral and positively
charged residues within the alphaC-beta4 loop. This interaction
with Hsp90 facilitates kinase maturation, activity and stability.
Inhibition of HSP90 leads to degradation of DAPK1 (Nair et al.,
2013).
The kinase domain of DAPK1 is followed by a Ca2+/CaM
autoregulatory domain, which suppresses catalytic activity by
binding to the catalytic cleft, and functions as a pseudosubstrate
(Shani et al., 2001; Shohat et al., 2001). The autoregulatory
domain binds to the catalytic cleft in the absence of CaM
and blocks access of exogenous substrates, thus inhibits
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FIGURE 2 | The crystal structure of the catalytic domain of DAPK1 with
ligand Phosphoaminophosphonic Acid-Adenylate Ester (ANP) and
Manganese (II) ion showing basic loop (blue) and H-bond interactions
with conserved amino acid residues (green).
DAPK1 function. The binding of CaM to the autoregulatory
domain pulls it away from catalytic cleft and enables substrate
phosphorylation. Thus, due to this inhibitory role, a mutant
DAPK1 lacking this domain (1CaM mutant) is constitutively
active in both in vitro and in vivo (Inbal et al., 2000). There
are several phosphorylation sites, located within the CaM
autoregulated domain, two of which Ser289 and Ser308, regulate
the DAPK1 activity. Here dephosphorylation of Ser308 increases
the affinity for the CaM thereby promoting the catalytic activity
at low CaM levels (Nair et al., 2013). Hence, DAPK1 is regulated
by a double-locking mechanism as full activation of DAPK1
requires two events: first, binding of Ca2+-activated CaM to
the autoregulatory/CaM-binding segment (Cohen et al., 1997;
Inbal et al., 2000; Lai et al., 2005); second, dephosphorylation
of Ser308 (Shani et al., 2001; Shohat et al., 2001). It has been
shown that the deletion of CaM-binding domain or substitution
of Ser308 to Ala, generates constitutively active form of DAPK1
thereby exhibiting greater Ca2+ independent catalytic activity
in vitro and strong killing potential in vivo (Cohen et al.,
1997; Inbal et al., 2000; Shani et al., 2001; Shohat et al.,
2001).
In summary, activation of DAPK1 requires two events: one,
common to all CaM dependent kinases, is binding of Ca2+-
activated CaM to the autoregulatory CaM-binding segment,
which pulls this domain out from the catalytic cleft. The other,
unique to DAPK1, is dephosphorylation of Ser308, increases the
affinity to CaM, facilitates the removal of the autoregulatory
domain from the catalytic cleft and promotes catalytic activity at
low Ca2+ level.
The Extracatalytic Domains
Ankyrin Repeats
DAPK1, at 160kDa, contains a large C- terminal extension
with multiple functional extensions with multiple functional
domains. It contains a series of 10 ankyrin repeats, which
facilitate protein-protein communications and are implicated
mostly in DAPK1 degradation (Nair et al., 2013). An alternatively
spliced product, s-DAPK-1, lacking the DAPK1 kinase domain
regulates the steady-state levels of the full-length DAPK1 and is
implicated in proteasome-independent degradation pathway for
DAPK1(Lin et al., 2009). The ankyrin repeats also facilitate the
degradation of DAPK1 via the ubiquitin-proteasome pathway.
The mindbomb E3 ubiquitin ligase 1 (MIB-1), also known
as DAPK-1 interacting protein i.e., DIP-1, is able to actively
ubiquitinate and degrade DAPK1 via interaction with ankyrin
repeats, affects its stability by mediating its proteasomal-
dependent degradation, or alternatively, helps in subcellular
localization (Jin et al., 2002). As DAPK1 interacts with HSP90
through its kinase domain, the E3 ubiquitin ligase carboxyl
terminus of HSC70-interacting protein (CHIP), which facilitates
the ubiquitination of HSP90-interacting proteins, will also
induce DAPK1 degradation (Connell et al., 2001; Zhang et al.,
2007). Deletion of the ankyrin repeats, which is protein-protein
interaction domain prominent in cytoskeletal proteins, can
cause mislocalization of DAPK1 from actin filaments to focal
adhesions.
ROC-COR Domain
Recently, DAPK1 was shown to be related to the ROCO family
of proteins, as it shares weak yet significant homology with the
ROCO proteins (Carlessi et al., 2011), which are multidomain
proteins, mostly kinases, characterized by having two domain
that always appear in tandem: the Ras of complex protein
(ROC) domain- a guanosine triphosphate (GTP)ase domain
similar to Ras and other small G-proteins- and immediately
downstream, the C-terminal of ROC (COR) domain. These
domains are located between 667–1288 residues of DAPK1.
DAPK1 binds GTP through a P-loop motif present in the
ROC domain (between the residues 695–702). The ROC-COR
domains promote GTP hydrolysis which indicates that DAPK1
is a GTP-binding protein with intrinsic GTPase activity. GTP-
binding is believed to suppress DAPK1 activity by enhancing
the inhibitory phospho-Ser308 within the same molecule,
through intramolecular signaling. Here GTP is hydrolyzed to
GDP by the ROC domain, resulting in some conformational
changes that are propagated to the N-terminus, which ultimately
decreases Ser308 autophosphorylation. Therefore this domain
provides an additional mechanism for the regulation of
DAPK1 activity, in a unique manner (Shiloh et al., 2014).
As in other ROCO family proteins, the ROC domain was
also shown to mediate DAPK1 homodimerization by both
its kinase domain and the ROC domain (Carlessi et al.,
2011).
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The ROC-COR domains, also called as cytoskeletal
localization domain, and can mediate an interaction with the
phosphor-Ser/Thr-directed peptidyl prolyl isomerase 1 (Pin1),
which is a critical signaling protein that modulates the function,
stability and/or localization of numerous phosphoproteins
through isomerization of proline that follows a phosphorylation
site (Lee et al., 2011). DAPK1 phosphorylates and inactivates
Pin1, thereby suppressing its cellular functions, including its
ability to induce cellular transformation (Shiloh et al., 2014).
Thus the ROC-COR domain serves not only to regulate DAPK1
catalytic activity, but can also mediate cellular functions through
protein-protein interactions.
Death Domain
The death domain is a protein-protein interaction mediating
domain that is common to many apoptosis-promoting
proteins, such as Fas, TNF receptor type 1-associated death
domain protein (TRADD), Fas-associated protein with
death domain (FADD) and Tumor necrosis factor (TNF)
receptor. In DAPK1, death domain is largely associated with
protein-protein interactions, kinase activity and apoptotic
functions. DAPK1’s death domain is located near its C-
terminus between residues 1312–1396, followed by a 17-aa
tail rich in Serine residues, a common feature in other
death domain-containing proteins (Feinstein et al., 1995).
The death domain of DAPK1 was suggested to mediate its
role in TNF-α and Fas-induced apoptosis, as transfection
of death domain fragment reduced TNF-α and Fas-
induced apoptosis, only in cells that expressed endogenous
DAPK1. Thus the deletion of the death domain affects the
apoptotic functions of TNF-α and Fas-induced cell death
(Cohen et al., 1999).
The death domain was shown to mediate an interaction
between extracellular-signal-regulated (ERK) and DAPK1 (Chen
et al., 2005). ERK causes an increase in DAPK1 catalytic activity
via phosphorylating DAPK1 on Ser735. In the mutant DAPK1
lacking the death domain, the activation of DAPK1 by ERK was
eliminated, highlighting a mechanism through which the death
domain may be necessary for full DAPK1 activity in cells (Shiloh
et al., 2014).
DAPK1’s death domain was also shown to mediate
interactions that promote degradation of DAPK1 by the
proteasome. It binds a beta -turn-beta (BTB)/Kelch protein,
Kelch-like protein 20 ( KLHL20) that act as an adaptor for the
Cullin3-ROC1 ubiquitin E3 ligase complex. IFN results in the
sequestration of KLHL20 away from DAPK1 cause high protein
level of DAPK1 upon IFN treatment (Lee et al., 2010).
The death domain was also shown to mediate an interaction
between DAPK1 and microtubule (MT) affinity regulating
kinases (MARK1/2). MARK is a Ser/Thr kinase that destabilizes
microtubules by phosphorylating tau (Wu et al., 2011). DAPK1
helps in relieving an inhibitory intramolecular interaction
between the catalytic and spacer regions of MARK1/2 by
activating it through the binding to its spacer region. Thus
DAPK1 promotes MARK1/2-induced MT destabilization
and neuronal differentiation which may also cause tau toxicity
and neurodegeneration.
A second effector, pyruvate kinase isoform M2 (PKM2) is
an isoform of the glycolytic enzyme, binds the death domain,
which is commonly expressed in cancer. DAPK1 leads to an
enhanced glycolytic rate and lactate production by activating
PKM2’s activity in vitro and in vivo (Mor et al., 2012). Thus a
particularly interesting aspect of the interaction of DAPK1 with
both MARK1/2 and PKM2 is that activating effect of DAPK1
on these proteins is mediated solely through binding, and is not
dependent on DAPK1 catalytic activity (Wu et al., 2011; Mor
et al., 2012).
Another interaction is between DAPK1’s death-domain and
death-domain containing protein Unc-5 homolog 2 (UNC5H2),
a dependence receptor which triggers apoptosis in the absence
of its ligand netrin-1. This interaction is probably mediated
through domains of both proteins as well as through additional
domains and was shown to be necessary for UNC5H5-induced
apoptosis, as co-transfection of a dominant-negative DAPK1
mutant together with UNC5H2 decreased cell death (Llambi
et al., 2005). Remarkably, overexpression of UNC5H2 activates
DAPK1 via dephosphorylation of Ser308 in a netrin-1 dependent
manner. Thus, this is another example of a role for the death
domain in promoting activation of DAPK1.
An additional interaction of DAPK1’s death domain is
with tuberous sclerosis 2 (TSC2), a negative regulator of the
mechanistic target of energy, growth factors and nutrient that
controls biosynthetic pathways and multiple cell growth (Stevens
et al., 2009). TSC2, as part of the TSC1/TSC2 dimer, act as a
GAP for the small GTPase protein Ras homolog enriched in brain
(Rheb) and activates mechanistic target of rapamycin (mTOR) in
its GTP–bound state. DAPK1’s interaction with TSC2 interferes
with TSC1 binding, and hence its ability to suppress mTOR.
Thus, there is a positive association between growth stimulation
of DAPK1 and mTOR1 signaling, which may ultimately affect
autophagy, cell survival, or apoptosis.
DAPK1 AND APOPTOSIS
The process of programmed cell death, or apoptosis, is defined
by the regulated destruction of cellular components either in
response to extrinsic (e.g., death receptor ligands) or intrinsic
(e.g., deoxyribonucleic acid (DNA) damage) stimuli, resulting
in death. Inappropriate apoptosis (either too little or too much)
is a cause of many human conditions including autoimmune
disorders, neurodegenerative diseases, ischemic damage and
many types of cancer (Elmore, 2007). The ability to regulate and
modulate the life or death of a cell is recognized for its immense
therapeutic potential. The apoptotic pathway consists of a series
of highly regulated steps, which include activation, propagation,
commitment and execution, are carried out by a diverse array of
signal transductionmechanisms including protein kinase activity
and subcellular localization via protein association domains
(Larner, 2000), such as those found in DAPK1 (Deiss et al., 1995;
Cohen et al., 1997).
In a number of cell culture models, DAPK1 has been
implicated in pathway leading to apoptosis and in some cases
may function prior to the commitment steps of the signal
transduction mechanism (Cohen et al., 1999; Raveh et al., 2001;
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Jang et al., 2002; Pelled et al., 2002; Yamamoto et al., 2002). Thus
some of the apoptotic properties of DAPK1 observed in cultured
cells will be responsible for certain aspects of human diseases.
A transforming growth factor (TGF)-β is related to DAPK1-
regulated pathways and apoptosis, which can stimulate apoptosis
in developing neurons and other tissues (De Luca et al., 1996;
Schuster and Krieglstein, 2002). Through a cell surface TGF-β
receptor, TGF-β initiates cellular actions and transmit the signal
inside the cell through Smads (Nakao et al., 1997), signaling
molecules that translocate to the nucleus and modulate gene
expression (Schuster and Krieglstein, 2002). The upregulation
of DAPK1 gene expression occurs due to TGF-β exposure,
requiring the function of Smad2, -3 and -4. In Hep3B hepatoma
cells, the DAPK1 gene expression was upregulated within 8 h,
consistent with the time course of TGF-β-induced apoptosis,
which is apparent between 8 and 18 h, suggesting that DAPK1
is an effector of the cell death program. Cells that express
DAPK1 death domain, are less sensitive to TGF-β-induced
apoptosis, suggesting that DAPK1 substrate phosphorylation
mediates TGF-β death signals and its death domain plays a role
in facilitating this (Jang et al., 2002). Despite the fact that DAPK1
mediated apoptosis in response to TGF-β is unclear; it is well
known that cytochrome c release from mitochondria causing
apoptotic protease activating factor 1 (Apaf1) activation and pro-
caspase 3 cleavage precedes TGF-β-induced apoptosis (Green
and Reed, 1998; Freathy et al., 2000).
DAPK1 has also been reported to mediate TNF-α and
IFN-γ induced apoptosis as well as by activation of the Fas
receptor (Cohen et al., 1999). Knockdown of DAPK1 by antisense
RNA protects HeLa cells from cell death induced by IFN-γ
and Fas. In addition, IFN-γ induced apoptosis is decreased
by expression of catalytically inactive DAPK1 (Cohen et al.,
1997). Cell death induced by p55 TNF-receptor activation is
also reduced by the expression of the DAPK1 death domain
(Cohen et al., 1999), which supports the role for this domain
in mediating cytokine-induced apoptosis. However, cell death is
not completely abrogated by either a death domain dominant
negative or a catalytically-inactive dominant negative, suggesting
that perhaps the death domain helps in localizing DAPK1 within
the cell so the catalytic activity of DAPK1 can function in
signaling networks (Schumacher et al., 2002).
In addition, many apoptotic signals for neurons, such as
excitotoxicity or exposure to DNA-damaging agents, invoke
cell death via the p53 pathway (Komarova and Gudkov, 2001).
Cell culture models have implicated DAPK1 in cytokine-
independent apoptosis via the p53 pathway (Raveh et al., 2001),
which has many functions including an active role in neuronal
regulation and development (Komarova and Gudkov, 2001),
and tumor suppression. Dissociation of p53 from the mouse
double minute 2 homolog (Mdm-2) protein and translocation
into nucleus cause the activation of p53 (Sherr, 1998). This
occurs when alternate reading frame (ARF) protein, human
p14ARF or mouse p19ARF, interacts with Mdm-2, causing its
dissociation from p53 (Sherr, 2001). It has been reported
that DAPK1 activates the p53 pathway via p19ARF through
an undetermined mechanism. In mouse embryonic fibroblasts
(MEFs), overexpression of constitutively active DAPK1 increases
levels of p53, p53-regulated proteins Mdm-2 as well as p21,
causing apoptosis (Raveh et al., 2001). A DAPK1 construct,
containing either a catalytically-inactive mutation of the kinase
domain or a deletion of the death domain, are unable to
induce cell death in rat embryonic fibroblasts (REFs) as a
wild type DAPK1 (Raveh et al., 2001), suggesting that DAPK1
mediates its effects on the p53 apoptotic pathway via its death
domain interaction and kinase activity, as it does in the cytokine
pathways. In DAPK1 or p53 knockout mice, the reduction of
apoptosis suggests that DAPK1 might be functioning upstream
of the commitment step in the p53 pathway, shows DAPK1 as
a potential target for the modulation of p53-mediated apoptosis
(Schumacher et al., 2002).
DAPK1 AND AUTOPHAGY
Recently, DAPK1 has been shown to be a critical regulator
of autophagy, a catabolic process whereby the cell engulfs
cytoplasmic organelles and contents in a double membrane
vesicle fuses with the lysosome, upon which its contents are
degraded. Autophagy serves as a quality control mechanism in
the cytoplasm by degrading long-lived proteins and scavenging
damaged organelles and misfolded proteins (Yang and Klionsky,
2010). Autophagic activity is greatly enhanced, under stress
conditions (e.g., starvation, oxidative stress, hypoxia,), to
facilitate removal of damaged organelles and proteins and/or
provide a source of recycled macromolecular building blocks
during nutrients deprivation and lack of energy. DAPK1 has been
recognized as a mediator of autophagic cell death by inducing a
non-apoptotic caspase-independent programmed cell death and
promoting the formation of autophagosome via increasing the
autophagy flux (Inbal et al., 2002; Zalckvar et al., 2009; Eisenberg-
Lerner and Kimchi, 2012).
Expression of DAPK1 leads to the enhanced formation of
autophagosomes in various cell types, which was observed as
an increase in the appearance of double membrane vesicles
enclosing cytoplasmic contents, indicates the varying states of
maturation of autophagosomes and autolysosomes (Inbal et al.,
2002).
Activation of DAPK1, by various stimuli that induce
autophagy, has been shown to involve several inter-related
mechanisms that include binding of Ca2+-activated CaM to the
CaM regulatory domain, (Cohen et al., 1997) dephosphorylation
of Ser308 by the PP2A phosphatase within the CaM regulatory
domain (Shohat et al., 2001; Gozuacik et al., 2008; Guenebeaud
et al., 2010; Widau et al., 2010), and potentially, hydrolysis of
GTP to GDP by the ROC-COR domains (Carlessi et al., 2011).
Activated DAPK1 positively contributes to the induction
stage of autophagosome nucleation via modulating the Vps34
class III phosphatidyl inositol 3-kinase complex by two
independent mechanisms. The first, a kinase cascade, involves
phosphorylation of protein kinase D (PKD) by DAPK1, which
further phosphorylates and activates Vps34. In the second
mechanism, DAPK1 directly phosphorylates Beclin1, a necessary
component of the Vps34 complex, thereby releasing it from its
inhibitors, B-cell lymphoma 2 (Bcl-2). Bcl-2 binds and inhibits
Beclin 1, preventing its association with the Vps34 complex.
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DAPK1 disrupts the Beclin 1/Bcl-2 interaction, in response to
ionomycin, via phosphorylation of Beclin 1 within the Bcl-2
homology domain 3 (BH3) domain. In response to starvation,
a Ser/Thr rho-associated, coiled-coil-containing protein kinase
1 (ROCK1) can also phosphorylate this residue. DAPK1
phosphorylates PKD, under oxidative stress, which in turn
phosphorylates and activates Vps34 directly. Activated Vps34
proceeds to phosphatidyl inositol-3 phosphate (PI3P) formation,
which recruits PI3P effector such as Double FYVE-domain
containing protein 1 (DFCP1), leading to autophagy. The
interaction of Beclin 1 with Bcl-2 interaction can be disrupted
by c-Jun N-terminal kinase (JNK)-mediated phosphorylation
of Bcl-2, binding of high mobility group box 1 (HMGB1) to
Beclin 1 or uniquitination of Beclin 1 by TNF receptor-associated
factor 6 (TRAF6). During oxidative stress, PKD can lead to JNK
phosphorylation through the mitogen-activated protein kinase
3K (MAPK3K) Apoptosis signal-regulating kinase 1 (ASK1);
it is not known if and when DAPK1 can modulate Bcl-2
through a PKD-JNK pathway (Figure 3; Levin-Salomon et al.,
2014).
The various scenarios, in which DAPK1 was shown to be
necessary for autophagy, have another factor in common: they
all involved cell death; but in some scenarios (e.g., ER stress,
oxidative stress) other death programs were also evident. As a
strong case for autophagic cell death was presented, i.e., death
was blocked by inhibition of autophagy and occurred in the
absence of another death program.
Although there are many regulators of autophagy but DAPK1
is unique in its potential to impact several different stages
within the autophagy flux pathway, including autophagosome
induction, trafficking and fusion. Some of these regulatory
events are more substantiated and proven than others but it
is not known what triggers these regulatory mechanisms, and
whether one or more are concurrently activated. Nevertheless,
by activating and enhancing multiple steps in the process,
DAPK1 has shown the potential for being an autophagy
‘‘super-activator’’ (Levin-Salomon et al., 2014). This may resolve
its relation specifically with autophagy associated with cell
death. Further research into the mechanisms by which DAPK1
regulates autophagy may reveal not only the function of
FIGURE 3 | Pathways linking DAPK1 to the nucleation step of autophagy through the Beclin 1-Vps34 complex formation in response to ionomycin
and under oxidative stress.
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DAPK1, but also the connection between autophagy and cell
death.
TARGETING DAPK1 IN CANCER AND
NEURODEGENERATIVE DISEASE
Recent research and reviews highlight communications between
cellular organelles under cancerous and neurodegenerative
conditions wherein endoplasmic reticulum stress, inflammation,
oxidative stress and autophagy are the signaling pathways
involved (Scherz-Shouval and Elazar, 2007; Alirezaei et al., 2011;
Doyle et al., 2011; Nixon, 2013; Chaudhari et al., 2014). Both
cancer and neurodegenerative disease have been linked with
misregulated autophagy, and to loss- and gain-of-function of
DAPK1, respectively. Thus it will be interesting to determine
DAPK1’s autophagic functions contribute to its role in these
pathologic conditions.
DAPK1 and Cancer
Although the relationship between cancer and autophagy
is a complex and often contradictory one as during early
stages, autophagy has a tumor suppressive function resulting
from its ability to suppress accumulation of p62 and the
generation of reactive oxygen species, and limit genomic
instability in response to metabolic stress and oxidative stress.
Autophagy also serves to prevent inflammation and tumor
necrosis (Tian et al., 2003; Degenhardt et al., 2006; Karantza-
Wadsworth et al., 2007; Mathew et al., 2007, 2009; White
et al., 2010; Lorin et al., 2013). In contrast, in later stages,
autophagy is necessary for tumor progression, for example
by providing nutrients and energy to the poorly vascularized
tumor and rapidly dividing tumor. Furthermore, autophagy
contributes to the resistance of tumor cells to radiation and
chemotherapy treatment by blocking apoptosis and alleviating
cellular stress. Significantly, Beclin 1, an autophagy gene has
been shown as tumor suppressor. Beclin 1 has been shown
to inhibit the functions of deubiquitinating enzymes that in
turn affect stability of p53, a master tumor suppressor (Liu
et al., 2011). Similarly, DAPK1’s ability to regulate autophagy
at different stages and its frequent epigenetic loss in tumor
may be connected. It has many different functions that
contribute to its ability to suppress metastasis and tumor
growth, which include its ability to upregulate p53 upon
oncogene expression (Raveh et al., 2001), to induce apoptosis
in response to loss of matrix attachment and cytotoxic
cytokines such as TNF-α (Inbal et al., 1997; Wang et al.,
2002), to activate pyruvate kinase M’s glycolytic function
(Mor et al., 2012), and to arrest cell motility and metastasis
(Kuo et al., 2006). Thus, it is unclear that as an autophagy
inducer, whether or not DAPK1’s function leads to tumor
suppression.
DAPK1 and Neurodegenerative Disease
DAPK1 has also been associated in the pathogenesis of neuronal
disorders such as epilepsy (Mor et al., 2012), Alzheimer’s disease
(AD; Li et al., 2006) and ischemic brain injury (Velentza et al.,
2003). This can be due to its ability to induce neuronal cell death
in response to ceramide, ischemia and glutamate toxicity (Pelled
et al., 2002; Tu et al., 2010).
Here we can target DAPK1 to prevent ischemic brain damage
by disrupting DAPK1-NR2B interaction promotes neuronal
death by potentiating functions of ‘‘calcium–activated death-
signaling proteins’’ in the NDC. An interference peptide,
Tat-NR2B-CT1292–1304, whose primary sequence includes the
membrane transducing domain of the HIV1 Tat protein
and the DAPK1-binding domain of NR2B, was developed to
prevent DAPK1-mediated NR2B subunit phosphorylation by
disrupting DAPK1-NR2B interaction, thereby NR2BR activity
potentiation, which attenuates excitotoxic neuronal injuries
(Lai et al., 2011). DAPK1 is also associated with late-onset
Alzheimer’s disease (LOAD). In terms of a possible role
in AD, two single nucleotide polymorphisms (SNPs) i.e.,
rs4878104 and rs4877365 are identified through the genotyping
of chromosome 9 in more than 2000 AD patients, located
within human DAPK1, suggested that the genetic variation in
DAPK1 modulates susceptibility to LOAD (Li et al., 2006). In
experimental animals, elevated DAPK1 activity was detected
in brains following ischemic injury and in animal and human
brain tissue following seizure-related injury (Henshall et al.,
2003, 2004). Bioavailable, small-molecule inhibitors of DAPK1
have been developed and these showed some protection in
animal models of acute brain injury (Schumacher et al.,
2002; Shamloo et al., 2005) and amyloid-induced hippocampal
damage (Craft et al., 2004). Recently it has been found that
the hippocampal DAPK1 expression is remarkably increased
in the brains of AD patients compared with age-matched
normal subjects (Kim et al., 2014). Here a novel role of
DAPK1 is identified in the regulation of tau protein (Wu
et al., 2011), a MT-associated protein, accumulates in AD
potentially as a result of posttranslational modifications, such
as hyperphosphorylation and conformational changes (Johnson
and Stoothoff, 2004). DAPK1 overexpression increases the tau
protein stability and phosphorylation at multiple AD-related
sites. In contrast, DAPK1 inhibition by genetic knockout or by
overexpression of a DAPK1 kinase-deficient mutant decreases
the tau protein stability and suppresses its phosphorylation.
In addition, inhibition of DAPK1 kinase activity significantly
increases the assembly of MTs and accelerates nerve growth
factor-mediated neurite outgrowth. As the DAPK1 is genetically
linked to LOAD, it has been suggested that DAPK1 is a
novel regulator of tau protein abundance, and upregulation
of DAPK1 might contribute to tau-related pathologies in AD.
Therefore, DAPK1 might be a novel therapeutic target for
the treatment of human AD and other tau-related pathologies
(Kim et al., 2014). Further it has been reported that DAPK1
phosphorylates tau protein at Ser262 (pS262) in cortical neurons
of stroke mice and either blocking DAPK1-tau interaction by
systematic application of a membrane permeable peptide or
genetic deletion of kinase domain (KD) in mice (DAPK1-
KD−/−) protects spine damage and improves neurological
functions against stroke insults. As the interaction of DAPK1-
KD has been confirmed with the MT repeat binding domain 1
of tau (R1D) consisting of amino acids IGSTENLK, recently,
a membrane-permeable peptide is generated by fusing the
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peptide IGSTENLK to the transduction domain of the HIV
TAT protein, named TAT-R1D. Treatment with TAT-R1D
(IGSTENLK) results in effective dissociation of DAPK1-tau
complexes and significant decrease in the level of pS262
causes apparent alleviation of infraction area as well as the
neurological deficits induced by cerebral ischemic stroke (Pei
et al., 2015). Thus, blocking DAPK1-tau interaction could be a
promising target for developing potential therapy for ischemic
stroke.
In addition, MT dynamics can be affected by DAPK1’s
activation of the MARK kinases, leading to taupathies (Wu et al.,
2011), through phosphorylating microtubule associated proteins
(MAPs) such as tau. However, the link between DAPK1’s role in
autophagy and neuropathologies is still unclear and remains an
important area for future research prospects.
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